Chronic kidney disease is not curable. Once kidney tissue is damaged and scarred, it does not regenerate or heal. However, that blunt answer only tells part of the story. Depending on how early CKD is caught and how aggressively it’s managed, many people can slow the disease to a near-standstill, preserve the kidney function they still have, and live full lives for decades.
Why Kidney Damage Is Permanent
Each kidney contains roughly one million tiny filtering units called glomeruli. When conditions like high blood pressure or diabetes damage these filters and their connected tubules, the tissue scars over. Unlike the liver, the kidneys cannot regrow lost filtering units. That scarring is what makes CKD a one-way process: you can protect the filters you still have, but you can’t bring back the ones already lost.
This is different from acute kidney injury, where a sudden insult (severe dehydration, a drug reaction, or a blockage) temporarily knocks kidney function down but the tissue itself isn’t scarred. Acute injuries that resolve within about 90 days often allow a full return to baseline. When kidney function stays depressed beyond that 90-day window, it’s generally reclassified as chronic, meaning permanent.
What the Stages Mean for Your Outlook
CKD is graded by how well your kidneys filter blood, measured as the glomerular filtration rate (GFR). The stages set expectations for what’s ahead:
- Stage 1 (GFR 90+): Normal filtering capacity, but other signs of kidney damage (protein in the urine, structural abnormalities) are present. Most people at this stage have no symptoms at all.
- Stage 2 (GFR 60–89): Mildly decreased function. Still usually symptom-free.
- Stage 3a (GFR 45–59) and 3b (GFR 30–44): Moderate loss. Fatigue, swelling, and changes in urination may start appearing.
- Stage 4 (GFR 15–29): Severe loss. Planning for dialysis or transplant typically begins here.
- Stage 5 (GFR below 15): Kidney failure. The kidneys can no longer sustain life without dialysis or a transplant.
Importantly, a GFR in the stage 1 or 2 range alone doesn’t qualify as CKD unless there’s additional evidence of kidney damage, such as protein leaking into the urine. If your doctor flags early-stage CKD, that protein measurement (called the albumin-to-creatinine ratio, or ACR) matters just as much as the GFR number for predicting how fast the disease will progress.
How Much Treatment Can Slow It Down
The goal of every CKD treatment plan is the same: keep the GFR from dropping further. Tight blood pressure control and blood sugar management remain the foundation, but a newer class of medication originally developed for diabetes has shifted expectations dramatically.
In a large real-world study of Japanese patients with CKD, those started on this newer drug class saw their kidney function decline nearly 0.75 points per year less than patients on older medications. That may sound small, but compounded over years it translates into major differences. Patients on the newer drugs had a 60% lower rate of serious kidney events, a 65% lower risk of losing half their remaining kidney function, and a 74% lower risk of reaching kidney failure compared to those on standard treatments. These drugs work in part by reducing the pressure inside the kidney’s filtering units, giving them a kind of mechanical relief.
Blood pressure medications that target the renin-angiotensin system remain standard as well, because they also reduce that intra-kidney pressure and limit protein leakage into the urine. The combination of these approaches can, in early-to-moderate stages, flatten the curve of decline enough that many patients never reach kidney failure in their lifetime.
Diet and Lifestyle Changes That Matter
What you eat has a measurable effect on how quickly CKD progresses. In a large prospective study of 900 adults, those eating predominantly plant-based diets had a 12% lower risk of GFR decline compared with those eating meat-heavy diets. Plant-based eating appears to reduce the amount of acid and waste products the kidneys need to process, effectively lowering their workload.
Sodium restriction is equally important. Excess salt raises blood pressure and increases the pressure inside kidney filters, accelerating damage. Most guidelines target well under 2,000 mg of sodium per day for CKD patients. Depending on the stage, your care team may also ask you to limit potassium, phosphorus, or total protein intake, because damaged kidneys struggle to balance these minerals. The specifics change as the disease progresses, so dietary recommendations at stage 2 look quite different from those at stage 4.
Regular physical activity, maintaining a healthy weight, and not smoking all independently slow kidney function loss. None of these reverse existing damage, but they reduce the strain on remaining nephrons and lower cardiovascular risk, which matters because heart disease is the leading cause of death in people with CKD, not kidney failure itself.
What Happens When Kidneys Fail
If CKD does progress to stage 5, two options sustain life: dialysis and transplantation. They are not cures. Dialysis mechanically filters the blood, either through a machine (hemodialysis, typically three sessions per week) or through the lining of the abdomen (peritoneal dialysis, often done daily at home). It replaces some filtering capacity but not the kidney’s hormonal and metabolic roles, which is why dialysis patients often still deal with fatigue, dietary restrictions, and complications like bone weakening.
Transplantation comes closer to restoring normal kidney function. Five-year survival for recipients of a living-donor kidney is about 85%, and for a deceased-donor kidney about 75%, according to the U.S. Renal Data System. Those numbers are significantly better than remaining on dialysis: among patients waitlisted for a transplant in 2017, nearly 19% had died within five years while still waiting. A transplanted kidney isn’t a cure either, though. Recipients take immune-suppressing medications for life to prevent rejection, and transplanted kidneys have a finite lifespan, often 15 to 20 years for a deceased-donor organ and sometimes longer for a living-donor one.
Experimental Approaches on the Horizon
Researchers are pursuing two ambitious ideas: regenerating kidney tissue with stem cells and building an implantable artificial kidney. Early-phase clinical trials are testing whether stem cells derived from umbilical cord tissue, delivered intravenously, can improve kidney function in people with stage 3 or 4 CKD. These trials are still in the Phase 1/2 stage, meaning they’re focused on safety and initial effectiveness. No results are available yet.
Meanwhile, the Kidney Project at UCSF is developing a surgically implantable device that combines a silicon filter with living kidney cells in a bioreactor, essentially a miniature kidney that would work continuously inside the body without the need for dialysis machines. The project is currently in preclinical testing, building and refining prototypes before moving to human trials. No timeline for commercial availability has been set.
Neither approach is close to clinical use. For now, the practical reality of CKD management centers on catching it early, controlling the conditions that caused it, using the medications available today to protect remaining function, and preparing for dialysis or transplant if and when the disease advances that far.